ABBV

AbbVie Inc.

7 filings tracked

healthcarebiotechnologyMEGA (>$200B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss

60%

bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion

40%

neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise

70%

bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change

50%

bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss

60%

bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion

40%

neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise

70%

bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change

50%

bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss

60%

bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion

40%

neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise

70%

bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change

50%

bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss

60%

bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion

40%

neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise

70%

bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change

50%

bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss

60%

bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion

40%

neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise

70%

bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change

50%

bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss

60%

bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion

40%

neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise

70%

bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change

50%

bearishMay 8

Net earnings attributable to AbbVie fell from $1.286 billion to $695 million YoY.

earnings miss

60%

bullishMay 8

Gross margin increased to 72% from 70% due to higher net revenues.

margin expansion

40%

neutralMay 8

Issued $8 billion in senior notes to manage liquidity and debt maturities.

capital raise

70%

bullishMay 8

Increased quarterly dividend to $1.73 per share.

dividend change

50%

Filing History

10-QMay 8, 2026

The Q1 2026 filing presents a company at a crossroads between operational success and balance sheet fragility. On one hand, the commercial execution of the immunology and neuroscience franchises is exemplary, proving that AbbVie can grow its top line even as its legacy blockbuster erodes. The strategic pivot toward a diversified portfolio is working, and the U.S. government agreement provides a critical short-term shield against political and regulatory volatility. However, the divergence between GAAP earnings and cash flow, fueled by heavy borrowing, raises questions about the sustainability of the current payout ratio. Investors must weigh the impressive 12% revenue growth against a mounting debt pile of $64.5 billion and the looming 2028 IRA price cliffs. The overall impact of the filing is a transition from a low-risk utility-like pharmaceutical stock to a higher-beta growth story where the primary trade-off is between immediate dividend yield and long-term solvency risks.